YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Legal questions swirl around FDA’s new expedited drug program, including who should sign off

Posted online

The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the agency, stoking worries that the plan may run afoul of legal, ethical and scientific standards long used to vet the safety and effectiveness of new medicines.

At the highest levels of the FDA, questions remain about which officials have the legal authority to sign off on drugs cleared under the Commissioner’s National Priority Voucher program, which promises approval in as little as one month for medicines that support “U.S. national interests.”

Read more from the Associated Press.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
From The Ground Up: Cheyenne Road multi-use trail with bridge

Complete with a 45-foot pedestrian bridge, this project adds a 10-foot-wide walking trail in front of Nixa’s High Pointe Elementary School and Summit Intermediate School.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences